Brentuximab Vedotin Plus Ifosfamide-Carboplatin-Etoposide in First Relapsed/Refractory Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia and Lymphoma
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study
Leukemia and Lymphoma 2022 Aug 17;[EPub Ahead of Print], A Stamatoullas, H Ghesquières, P Feugier, M André, F Le Bras, AC Gac, C Borel, T Gastinne, P Quittet, F Morschhauser, V Ribrag, S Guidez, E Nicolas-Virelizier, A Berriolo-Riedinger, T Vander Borght, V Edeline, P BriceFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.